Overview

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Status:
Active, not recruiting
Trial end date:
2022-04-18
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are: - To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH) - To evaluate the long-term safety and tolerability of evinacumab in adolescent patients with HoFH The secondary objectives of the study are: - To evaluate the effect of evinacumab on lipid parameters in patients with HoFH - To evaluabe the effect of evinacumab on lipd parameters in adolescent patients with HoFH - To evaluate the potential development of anti-evinacumab antibodies
Phase:
Phase 3
Details
Lead Sponsor:
Regeneron Pharmaceuticals